

## EQA round: GP2/24 - Detection of Monoclonal Components

Deadline: 20.9.2024

Setup: Slovakia

AV = assigned value	N <sub>tot</sub> = total number of the results	N <sub>eva</sub> = number of the results assessed
CVP = consensus of all participants	N <sub>rel</sub> = relative number of the results	N <sub>suc</sub> = number of successful results
>>> ... expected result		S <sub>rel</sub> = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>Set 1 (plasma)</b>							
(246) <b>Gammopathies (typisation) (plasma)</b>		17			17	16	94
<b>Sample A1</b>		17			17	17	100
All results	CVP >>>	17	100	IgG-lambda			
<b>Sample B1</b>		17			17	16	94
All results	CVP >>>	16	94	IgM-kappa			
		1	5,9	IgM-kappa; lambda-free			
<b>Set 2 (urine)</b>							
(540) <b>Gammopathies (typisation) (urine)</b>		15			15	11	73
<b>Sample A2</b>		15			15	12	80
All results	CVP >>>	9	60	kappa-free			
		1	6,7	kappa-free; IgA-kappa			
	>	3	20	kappa-free; kappa			
		1	6,7	kappa-free; kappa; lambda			
		1	6,7	kappa-free; lambda-free			
<b>Sample B2</b>		15			15	14	93
All results	CVP >>>	9	60	kappa-free			
	>	2	13	kappa-free; IgA-kappa			
	>	3	20	kappa-free; kappa			
		1	6,7	kappa-free; kappa; IgA-kappa			